Wells Fargo & Company MN Acquires New Position in Upstream Bio, Inc. (NASDAQ:UPB)

Wells Fargo & Company MN purchased a new stake in Upstream Bio, Inc. (NASDAQ:UPB) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 9,047 shares of the company’s stock, valued at approximately $149,000.

Other large investors have also recently bought and sold shares of the company. Moody Aldrich Partners LLC acquired a new stake in shares of Upstream Bio in the fourth quarter valued at approximately $1,229,000. Rhumbline Advisers acquired a new position in Upstream Bio in the 4th quarter valued at about $275,000. Bank of New York Mellon Corp acquired a new stake in shares of Upstream Bio during the 4th quarter worth about $607,000. US Bancorp DE purchased a new position in shares of Upstream Bio during the fourth quarter valued at approximately $27,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in Upstream Bio in the 4th quarter valued at $2,225,000.

Upstream Bio Trading Down 1.2 %

Upstream Bio stock opened at $8.73 on Friday. The stock has a fifty day moving average price of $8.03 and a 200 day moving average price of $13.58. Upstream Bio, Inc. has a 52 week low of $5.14 and a 52 week high of $29.46.

Upstream Bio (NASDAQ:UPB) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.02). The business had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.71 million. On average, analysts anticipate that Upstream Bio, Inc. will post -4.3 earnings per share for the current year.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.